BioWorld MedTech

Feb. 20, 2013

SEMDA 2013: Leahey: med-tech firms' voices still matter despite difficulties

ATLANTA — Some would say that in recent years the landscape for med-tech has been littered with difficulties and challenges often resulting in many devicemakers feeling as if their voice has been diminished. Read More

NewCo on the Go: ForeCYTE test like Pap smear for breast cancer

Report from Europe: Dune Medical in compliance for next-gen MarginProbe

Washington roundup: Neiman Institute offers rubric for evaluating repeat imaging

Financings roundup: PolyActiva raises more than $9M in Series B funding round

Agreements/contracts: Laser Spine partners with Marodyne for LivMD device

Deals roundup: Liaison sees opportunities in HIT via Ignis acquisition

HIT roundup: EMH Healthcare goes live on Capsule's MVP

Med-Tech Notes

People in the News

Product Briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for Feb. 14, 2025.

European VCs optimistic for med-tech exit opportunities in 2025

BioWorld MedTech

To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for February 14, 2025

European VCs bullish on med-tech investments in 2025

BioWorld MedTech

European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...

3D illustration of acute myeloid leukemia cells

Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML

BioWorld

Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...